Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bladder Cancer

  Free Subscription

Articles published in
Oncogene
    March 2021
  1. ZHENG R, Du M, Ge Y, Gao F, et al
    Identification of low-frequency variants of UGT1A3 associated with bladder cancer risk by next-generation sequencing.
    Oncogene. 2021 Mar 3. pii: 10.1038/s41388-021-01672.
    >> Share

    February 2021
  2. YAN Q, Zeng P, Zhou X, Zhao X, et al
    RBMX suppresses tumorigenicity and progression of bladder cancer by interacting with the hnRNP A1 protein to regulate PKM alternative splicing.
    Oncogene. 2021 Feb 9. pii: 10.1038/s41388-021-01666.
    >> Share

    January 2021
  3. XIONG Y, Ju L, Yuan L, Chen L, et al
    KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer.
    Oncogene. 2021 Jan 15. pii: 10.1038/s41388-020-01634.
    >> Share

    December 2020
  4. ROSE M, Maurer A, Wirtz J, Bleilevens A, et al
    Correction: EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.
    Oncogene. 2020 Dec 1. pii: 10.1038/s41388-020-01534.
    >> Share

    October 2020
  5. JIA Y, Ding X, Zhou L, Zhang L, et al
    Mesenchymal stem cells-derived exosomal microRNA-139-5p restrains tumorigenesis in bladder cancer by targeting PRC1.
    Oncogene. 2020 Oct 29. pii: 10.1038/s41388-020-01486.
    >> Share

  6. JIN Y, Zhou Y, Deng W, Wang Y, et al
    Genome-wide profiling of BK polyomavirus integration in bladder cancer of kidney transplant recipients reveals mechanisms of the integration at the nucleotide level.
    Oncogene. 2020 Oct 13. pii: 10.1038/s41388-020-01502.
    >> Share

    September 2020
  7. ROSE M, Maurer A, Wirtz J, Bleilevens A, et al
    EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.
    Oncogene. 2020 Sep 25. pii: 10.1038/s41388-020-01465.
    >> Share

    August 2020
  8. VANTAKU V, Putluri V, Bader DA, Maity S, et al
    Correction: Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression.
    Oncogene. 2020 Aug 17. pii: 10.1038/s41388-020-1283.
    >> Share

    March 2020
  9. CHANDRASHEKAR DS, Chakravarthi BVSK, Robinson AD, Anderson JC, et al
    Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression.
    Oncogene. 2020 Mar 30. pii: 10.1038/s41388-020-1275.
    >> Share

  10. LIU X, Cui J, Gong L, Tian F, et al
    The CUL4B-miR-372/373-PIK3CA-AKT axis regulates metastasis in bladder cancer.
    Oncogene. 2020 Mar 3. pii: 10.1038/s41388-020-1236.
    >> Share

    December 2019
  11. LIU HJ, Lam HC, Baglini CV, Nijmeh J, et al
    Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor beta (RARbeta).
    Oncogene. 2019;38:7367-7383.
    >> Share

    November 2019
  12. YANG R, Xu J, Hua X, Tian Z, et al
    Overexpressed miR-200a promotes bladder cancer invasion through direct regulating Dicer/miR-16/JNK2/MMP-2 axis.
    Oncogene. 2019 Nov 26. pii: 10.1038/s41388-019-1120.
    >> Share

  13. LIU F, Zhang H, Xie F, Tao D, et al
    Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis.
    Oncogene. 2019 Nov 8. pii: 10.1038/s41388-019-1092.
    >> Share

    October 2019
  14. OSEI-AMPONSA V, Buckwalter JM, Shuman L, Zheng Z, et al
    Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer.
    Oncogene. 2019 Oct 21. pii: 10.1038/s41388-019-1063.
    >> Share

    September 2019
  15. CHEN J, Chou F, Yeh S, Ou Z, et al
    Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Galphai protein/MAPK/MMP9 intracellular signaling.
    Oncogene. 2019 Sep 10. pii: 10.1038/s41388-019-0964.
    >> Share

    August 2019
  16. VANTAKU V, Putluri V, Bader DA, Maity S, et al
    Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression.
    Oncogene. 2019 Aug 5. pii: 10.1038/s41388-019-0902.
    >> Share

    May 2019
  17. PALMBOS PL, Wang Y, Bankhead Iii A, Kelleher AJ, et al
    ATDC mediates a TP63-regulated basal cancer invasive program.
    Oncogene. 2019;38:3340-3354.
    >> Share

    March 2019
  18. WU M, Sheng L, Cheng M, Zhang H, et al
    Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells.
    Oncogene. 2019 Mar 27. pii: 10.1038/s41388-019-0799.
    >> Share

    January 2019
  19. CHENG M, Sheng L, Gao Q, Xiong Q, et al
    The m(6)A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-kappaB/MYC signaling network.
    Oncogene. 2019 Jan 18. pii: 10.1038/s41388-019-0683.
    >> Share

  20. ZHU J, Huang G, Hua X, Li Y, et al
    CD44s is a crucial ATG7 downstream regulator for stem-like property, invasion, and lung metastasis of human bladder cancer (BC) cells.
    Oncogene. 2019 Jan 11. pii: 10.1038/s41388-018-0664.
    >> Share

    July 2018
  21. LEE E, Collazo-Lorduy A, Castillo-Martin M, Gong Y, et al
    Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR.
    Oncogene. 2018 Jul 3. pii: 10.1038/s41388-018-0367.
    >> Share

  22. LIU JY, Zeng QH, Cao PG, Xie D, et al
    SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival.
    Oncogene. 2018;37:3937-3952.
    >> Share

    June 2018
  23. PENG M, Wang J, Zhang D, Jin H, et al
    PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein.
    Oncogene. 2018 Jun 21. pii: 10.1038/s41388-018-0374.
    >> Share

    May 2018
  24. ROUDNICKY F, Yoon SY, Poghosyan S, Schwager S, et al
    Alternative transcription of a shorter, non-anti-angiogenic thrombospondin-2 variant in cancer-associated blood vessels.
    Oncogene. 2018;37:2573-2585.
    >> Share

  25. LIU Q, Gheorghiu L, Drumm M, Clayman R, et al
    PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
    Oncogene. 2018;37:2793-2805.
    >> Share

    March 2018
  26. SHEN P, Jing Y, Zhang R, Cai MC, et al
    Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics.
    Oncogene. 2018 Mar 14. pii: 10.1038/s41388-018-0192.
    >> Share

    February 2018
  27. HSIEH HY, Jou YC, Tung CL, Tsai YS, et al
    Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment.
    Oncogene. 2018;37:673-686.
    >> Share

    January 2018
  28. FANTINI D, Glaser AP, Rimar KJ, Wang Y, et al
    A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer.
    Oncogene. 2018 Jan 25. pii: 10.1038/s41388-017-0099.
    >> Share

    May 2017
  29. HAN AL, Veeneman BA, El-Sawy L, Day KC, et al
    Fibulin-3 promotes muscle-invasive bladder cancer.
    Oncogene. 2017 May 15. doi: 10.1038/onc.2017.
    >> Share

    March 2017
  30. WAN W, Peng K, Li M, Qin L, et al
    Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1alpha.
    Oncogene. 2017 Mar 6. doi: 10.1038/onc.2017.
    >> Share

    October 2016
  31. ZHANG H, Ye YL, Li MX, Ye SB, et al
    CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer.
    Oncogene. 2016 Oct 10. doi: 10.1038/onc.2016.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016